Capricor Therapeutics Inc. (CAPR)
NASDAQ: CAPRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CAPR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $441.30M
- EPS (TTM)
- -$2.65
- Dividend yield
- None
- 52-week range
- 2.96 – 40.37
- Day range
- 7.38 – 8.34
- Volume / Avg
- 10.65M / 4.73M
- Beta
- —
- Shares outstanding
- 58.14M
52-week range
CAPR stock today
Shares of Capricor Therapeutics (CAPR) finished higher on Nov 20 at $7.59, a gain of 0.80% or $0.06 per share, versus the S&P 500's 3.70% decline. Volume was 2.2x the average at 10.65M shares, a sign of unusually heavy trading. At this level, CAPR sits near the bottom of its 52-week range of $2.96 to $40.37: 81.2% below the high, set on Dec 3, 2025 and 156.4% above the low.
CAPR is down 73.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 32.0%. Capricor Therapeutics has posted a net loss over the last twelve months (EPS of -$2.65), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Capricor Therapeutics
Company profileCapricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Linda Marbán Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 231
- Website
- capricor.com
Financial highlights
Full financialsIn fiscal 2025, Capricor Therapeutics generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Capricor Therapeutics reported a net loss of $105.0 million, compared with a loss of $40.5 million a year earlier. Diluted earnings per share came in at -$2.26.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $22.27M | $25.18M | $2.55M | $244.90K |
| Growth | -100.00% | -11.55% | +886.81% | +941.85% | -21.06% |
| Net income | $-105.04M | $-40.47M | $-22.29M | $-29.02M | $-20.02M |
| EPS (diluted) | $-2.26 | $-1.15 | $-0.83 | $-1.18 | $-0.87 |
Analyst forecast
ForecastConsensus (10 analysts)
buy
Avg. price target
$27.25+259.03%
- Strong buy 1
- Buy 4
- Hold 5
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.54 vs $-0.61
- Surprise
- +11.48%
CAPR news
All CAPR news- Capricor Plunges On Regulatory Setback As FDA Declines To Approve Deramiocel For DuchenneNasdaqCAPR, HEI.A
- Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular DystrophyGlobeNewswire
- Noteworthy Thursday Option Activity: ALLY, CAPR, GFLNasdaqALLY, CAPR, GFL, BF.A
- Notable Wednesday Option Activity: AAP, CAPR, FSLRNasdaqAAP, CAPR, FSLR
- The Making, Unmaking And Hope Of Capricor Therapeutics (CAPR)NasdaqCAPR, BRK.A
- Capricor Therapeutics shares rise as FDA decision nearsSeeking Alpha
- Capricor Therapeutics GAAP EPS of -$0.73 misses by $0.31Seeking Alpha
- Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
Capricor Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AQSTAquestive Therapeutics Inc. | 3.46 | -6.61% | $434.88M | vs CAPR |
| LYELLyell Immunopharma Inc. | 13.80 | +1.62% | $441.82M | vs CAPR |
| INDPIndaptus Therapeutics Inc. | 2.82 | -9.90% | $433.16M | vs CAPR |
| CTMXCytomX Therapeutics Inc. | 2.03 | -0.98% | $442.55M | vs CAPR |
| EOLSEvolus Inc. | 6.52 | -6.86% | $431.55M | vs CAPR |
| AMRNAmarin Corporation plc | 10.57 | -6.13% | $444.39M | vs CAPR |
| DMACDiaMedica Therapeutics Inc. | 8.25 | +2.87% | $445.15M | vs CAPR |
| KMDAKamada Ltd. | 7.74 | -1.15% | $446.85M | vs CAPR |
Indexes, lists and sector
Capricor Therapeutics stock FAQ
What is Capricor Therapeutics's stock price today?
CAPR last traded at $7.59 as of Nov 20, 4:00 PM EST, up 0.80% on the day. Prices are delayed at least 15 minutes.
Does Capricor Therapeutics pay a dividend?
No. Capricor Therapeutics does not currently pay a regular cash dividend.
Who is Capricor Therapeutics's CEO?
Dr. Linda Marbán Ph.D. is the chief executive officer of Capricor Therapeutics Inc., which has about 231 employees.
Has CAPR ever split its stock?
Yes. The most recent CAPR stock split was a 1-for-10 split on Jun 5, 2019, one of 2 splits on record.
What is the CAPR 52-week high?
The 52-week high for CAPR is $40.37 and the 52-week low is $2.96. The stock is currently 81.2% below its high.